Denali Therapeutics (DNLI) Insider Trading & Ownership $15.65 +0.05 (+0.32%) Closing price 04:00 PM EasternExtended Trading$15.47 -0.18 (-1.15%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Denali Therapeutics (NASDAQ:DNLI) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage12.50%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$10.97M Get DNLI Insider Trade Alerts Want to know when executives and insiders are buying or selling Denali Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DNLI Insider Buying and Selling by Quarter Denali Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/13/2025Carole HoInsiderSell806$14.64$11,799.84 8/12/2025Alexander O SchuthInsiderSell2,937$13.58$39,884.46 8/12/2025Carole HoInsiderSell2,937$13.58$39,884.46 7/9/2025Ryan J WattsCEOSell495,282$15.00$7,429,230.00 1/7/2025Steve E KrognesDirectorSell3,339$20.81$69,484.59 1/6/2025Carole HoInsiderSell12,255$20.22$247,796.10 1/6/2025Ryan J WattsCEOSell29,266$20.22$591,758.52 1/2/2025Vicki L SatoDirectorSell3,080$20.91$64,402.80 11/7/2024Alexander O SchuthInsiderSell15,558$29.91$465,339.78 11/7/2024Vicki L SatoDirectorSell1,020$30.00$30,600.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 10/18/2024Ryan J WattsCEOSell40,000$27.69$1,107,600.00 9/30/2024Steve E KrognesDirectorSell30,000$29.03$870,900.00 (Data available from 1/1/2013 forward) DNLI Insider Trading Activity - Frequently Asked Questions Who is on Denali Therapeutics' Insider Roster? The list of insiders at Denali Therapeutics includes Alexander O Schuth, Carole Ho, Jennifer E Cook, Marc Tessier-Lavigne, Ryan J Watts, Steve E Krognes, and Vicki L Sato. Learn more on insiders at DNLI. What percentage of Denali Therapeutics stock is owned by insiders? 12.50% of Denali Therapeutics stock is owned by insiders. Learn more on DNLI's insider holdings. Which Denali Therapeutics insiders have been selling company stock? The following insiders have sold DNLI shares in the last 24 months: Alexander O Schuth ($505,224.24), Carole Ho ($630,157.08), Jennifer E Cook ($31,682.34), Ryan J Watts ($9,788,717.06), Steve E Krognes ($3,625,105.05), and Vicki L Sato ($331,374.88). How much insider selling is happening at Denali Therapeutics? Insiders have sold a total of 831,060 Denali Therapeutics shares in the last 24 months for a total of $14,912,260.65 sold. Denali Therapeutics Key ExecutivesDr. Ryan J. Watts Ph.D. (Age 48)Co-Founder, President, CEO & Director Compensation: $1.15MDr. Alexander O. Schuth M.D. (Age 51)Co-Founder, CFO, COO & Secretary Compensation: $802.29k1 recent tradesDr. Marc Tessier-Lavigne Ph.D. (Age 64)Co-Founder & Independent Director Compensation: $57.5kDr. Carole Ho M.D. (Age 51)Chief Medical Officer & Head of Development Compensation: $802.29kMr. Tyler M. Nielsen (Age 46)Senior Vice President of Corporate Finance Dr. Dana AndersenChief Technical and Manufacturing OfficerMr. Joe Lewcock Ph.D.Chief Scientific OfficerDr. Laura HansenVice President of Investor RelationsMr. Chris WalshGeneral CounselMr. Mark RowenVice President of Corporate Development More Insider Trading Tools from MarketBeat Related Companies BEAM Insider Ownership BPMC Insider Ownership ROIV Insider Ownership GRFS Insider Ownership RVMD Insider Ownership RYTM Insider Ownership RNA Insider Ownership AXSM Insider Ownership NUVL Insider Ownership CRSP Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Costco Faces Downgrades, Death Cross, Insider SellingReynolds Consumer Products Stock Price: Insiders Signal a BottomBuy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say Buy This page (NASDAQ:DNLI) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access